EU funding for MedTech startups runs through a small number of major instruments. Horizon Europe as the multi-year research and innovation framework, the EIC Accelerator as the flagship single-company instrument, EIT Health as the health-focused knowledge and innovation community, and the Innovation Fund and related programmes at the edges. Each operates on a different logic, funds a different kind of work, and fits a different moment in a MedTech startup's life. At general framing, the winning pattern is the same across all of them: understand what each instrument is actually for, match it to the work you would be doing anyway, and never let a funded scope drift away from the real project.

By Felix Lenhard and Tibor Zechmeister. Last updated 10 April 2026.

TL;DR

  • The EU funding stack for MedTech startups is made up of a small number of major instruments that each operate on a different logic. Horizon Europe, the EIC Accelerator, EIT Health, and the Innovation Fund and related edge programmes.
  • Horizon Europe is the multi-year EU research and innovation framework programme and typically funds collaborative consortia rather than single companies.
  • The EIC Accelerator is the European Innovation Council's flagship single-company instrument and historically the largest non-dilutive source of EU-level capital available to an individual MedTech startup.
  • EIT Health is the health-focused knowledge and innovation community under the European Institute of Innovation and Technology, operating a portfolio of accelerator, matching, and translation programmes.
  • Every figure, call, and eligibility criterion for every instrument described here shifts between work programmes and cycles. Treat this post as orientation, not a guarantee of what is open today. Verify current terms directly at the Commission's portals before any number enters a plan.
  • Every euro of EU funding still sits under the full obligations of Regulation (EU) 2017/745, Article 10. The funding source does not change the regulatory burden; it changes how you finance meeting it.

Why the EU layer matters for MedTech founders

For a European MedTech startup, the EU funding layer sits above the national and regional layers of the non-dilutive stack. It is not the only source of capital, and for many companies it is not even the largest one in absolute terms. The national stacks in countries like Germany, France, and Austria often contribute more capital in the first few years than any EU instrument does. But the EU layer has a distinct role that the national layers cannot play. The ticket sizes at the top of the EU stack are large. The validation signal that comes with an EU award travels across borders in a way that a single-country grant rarely does. And for companies whose ambition is pan-European or global from the start, the EU layer is the funding layer that matches the scope of the project.

The difficulty of the EU layer is that it is more fragmented than founders expect. The stack is not one programme with one application. It is a portfolio of instruments with different histories, different administering bodies, different evaluation cultures, and different fits for different kinds of work. A founder who treats "EU funding" as one thing ends up applying to the wrong instrument, writing the wrong kind of application, and losing months to a process that was never going to fit the project in the first place.

This post is the orientation at general framing. What each major instrument is for, how they sit alongside each other, and how a MedTech founder should think about sequencing between them. For the broader non-dilutive landscape this layer sits inside, the parent post is non-dilutive funding for MedTech startups.

The EU funding stack at general framing

At general framing, the EU funding stack for MedTech startups has four visible pieces and a wider edge.

The first piece is Horizon Europe, the European Union's multi-year framework programme for research and innovation. It is the largest single research funding programme in the world by absolute budget and covers everything from fundamental science through applied research to close-to-market innovation. For MedTech, Horizon Europe is typically accessed through collaborative calls that fund consortia of partners across multiple member states working together on a shared research problem.

The second piece is the EIC Accelerator, run by the European Innovation Council inside the Horizon Europe framework but operating as its own instrument. The EIC Accelerator is specifically aimed at single high-potential companies, combines grant funding with an equity-style investment component, and is the single largest EU-level non-dilutive instrument an individual MedTech startup can target on its own.

The third piece is EIT Health, the health-focused knowledge and innovation community under the European Institute of Innovation and Technology. EIT Health is not a single programme but a portfolio of accelerator, matching, translation, and training programmes operating through a network of regional hubs across Europe, with a specific focus on health and MedTech projects.

The fourth piece is the EU Innovation Fund and related edge programmes. Instruments like the Innovation Fund, Digital Europe, EU4Health, InvestEU-linked guarantees, and the European Investment Fund instruments that reach MedTech startups indirectly. Most of these do not target MedTech as their primary audience, but each one has touched MedTech projects where the fit was right.

The working rule for a founder new to the stack is not to apply to all of it. It is to understand what each instrument is for, shortlist the one or two that actually fit the project, and then do the serious work of preparing a strong application for those. Not a rushed application for five.

Horizon Europe at general level

Horizon Europe is the current multi-year EU research and innovation framework programme. It is organised into pillars covering excellent science, global challenges and European industrial competitiveness, and innovative Europe, with the European Innovation Council sitting under the third pillar. For MedTech startups, the parts of Horizon Europe that matter most are the collaborative calls in the health cluster of the second pillar and the EIC instruments in the third pillar.

The characteristic feature of Horizon Europe collaborative calls is that they fund consortia rather than single companies. A typical call invites proposals from partnerships of several organisations. Universities, research institutes, hospitals, companies of different sizes. Across multiple member states, working on a shared research question defined in the call text. For a MedTech startup, this usually means joining an existing consortium as one partner among several rather than leading a proposal as the sole applicant.

The advantages of the collaborative route for a MedTech startup are the access to research infrastructure and clinical partners the company could not build on its own, the credibility that comes with being inside an EU-funded consortium, and the funding for specific research work packages that would otherwise have to come from equity. The disadvantages are the pace. Horizon Europe consortia move on research time, not commercial time. And the scope constraint, because the consortium's shared workplan may not match the startup's commercial priorities exactly.

Specific Horizon Europe calls, budgets, consortium rules, and evaluation criteria are defined in the current work programme and change through the framework's cycles. Every number or rule from this post or any other must be verified at the Commission's current portals before it is treated as settled. For deeper framing of this instrument, see Horizon Europe for MedTech startups.

EIC Accelerator specifics at general level

The EIC Accelerator is the European Innovation Council's flagship single-company instrument for high-potential deep-tech and deep-science innovation. Unlike Horizon Europe collaborative calls, the EIC Accelerator funds individual companies rather than consortia, and the applications are led by the company itself.

At general framing, the instrument has historically bundled two components. A grant component funds the innovation activities that sit between proven technology and first commercial revenue. Prototype refinement, validation work, regulatory activities, pilot deployments, early go-to-market work. An equity-style investment component, offered alongside the grant, can sit on the cap table next to private investors on terms the company can evaluate case by case.

The programme runs in competitive stages. An initial short application, a full proposal, and a final interview in front of an evaluation panel. With attrition at each stage. The panels include MedTech specialists for MedTech submissions, and the evaluation is serious enough that a rushed application has no realistic chance.

For MedTech startups specifically, the EIC Accelerator is valuable when the project is genuine deep technology or deep science, when the regulatory path is a meaningful component of the total cost, and when the team has a credible commercial story that a pure research grant would not support. It is not the right instrument for me-too devices, marginal improvements, or pure commercial scale-up. Specific amounts, cut-off dates, and eligibility criteria move between work programmes and must be verified at the European Innovation Council portal before any figure enters a plan. The dedicated spoke post is EIC Accelerator for MedTech: how to write a winning application.

EIT Health at general level

EIT Health is the health-focused knowledge and innovation community under the European Institute of Innovation and Technology. It is structurally different from Horizon Europe and the EIC Accelerator. Where Horizon Europe is a framework programme with open calls and the EIC Accelerator is a single instrument with a defined application cycle, EIT Health is a network. A partnership of universities, research institutes, hospitals, and companies across Europe that collectively operate a portfolio of programmes aimed at health innovation.

The programmes that sit under EIT Health cover accelerator tracks for early-stage companies, translation programmes that bridge research and commercialisation, matching and cross-border deal-flow programmes that connect startups with clinical partners and investors, and education programmes that train talent into the health sector. For a MedTech startup, the most directly relevant pieces are usually the accelerator and translation programmes, which offer a combination of funding, mentoring, clinical access, and network reach that pure grant programmes do not.

The character of EIT Health as a network rather than a single grant line matters for how founders should approach it. Applying to EIT Health is less like filling out one application form for one envelope of money and more like joining a community that operates a portfolio of opportunities over time. The value compounds for founders who engage seriously across multiple touch-points rather than applying to one programme and walking away.

As with every other piece of the EU stack, specific EIT Health programmes, budgets, eligibility criteria, and application cycles shift between years and between the regional hubs that operate them. Treat this section as a map of the shape of the instrument, not a catalogue of current calls.

The Innovation Fund and edge programmes

Beyond Horizon Europe, the EIC Accelerator, and EIT Health, a wider edge of EU-level instruments occasionally reaches MedTech projects. The Innovation Fund, Digital Europe, EU4Health, InvestEU-linked guarantees, and various European Investment Fund instruments each have a primary audience that is usually not MedTech, but each has supported MedTech work where the fit was right. Digital health projects inside Digital Europe calls, health-system infrastructure work inside EU4Health, deep-tech ventures inside InvestEU-guaranteed loan instruments.

The honest framing of these edge programmes is that they are not where most MedTech startups should start. The fit is narrower, the effort-to-signal ratio is harder to judge, and the probability that a given programme is the right home for a specific MedTech project is low compared to the three main instruments above. But for founders whose project sits at the boundary of MedTech and another sector. Health data, environmental health, digital infrastructure, dual-use technology. The edge programmes are worth scanning, because the programmes that target those boundaries directly often have less competition than the main MedTech-adjacent routes.

The rule is the same one that applies to the whole EU stack. Understand what each instrument is actually for before applying. Match the instrument to the project, not the project to the instrument.

How to sequence EU applications

The sequencing question inside the EU stack is not "which instrument first and then the next one." It is "which one or two instruments actually fit this project, and when in the company's life do those applications make sense?"

A practical working pattern. First, early in the company's life, when the innovation is closer to research than to market, the Horizon Europe consortium route is often the most accessible EU-level option. Joining an existing consortium as one partner, contributing the company's specific capability, and drawing down a share of the research budget. Second, once the innovation has moved past pure research and the company has a credible commercial plan and a serious regulatory plan, the EIC Accelerator becomes the flagship target, with months of preparation leading up to a serious full application. Third, throughout the company's life, EIT Health is worth engaging with on an ongoing basis rather than as a single application. The network value compounds for founders who show up across multiple touch-points over time.

Running applications in parallel is possible where the instruments are complementary rather than mutually exclusive, and much of the core material on the innovation, the team, and the regulatory plan is reusable across submissions. What does not work is spreading thin. Writing four half-prepared applications at the same time to four instruments that are each competitive enough to reject half-prepared work. Better to prepare one strong submission for the instrument that actually fits than four rushed submissions for instruments that do not.

The sequencing inside the national and regional layers of the non-dilutive stack runs alongside the EU layer, not after it. For the full picture of how the EU layer interacts with national programmes, see non-dilutive funding for MedTech startups and Austrian funding for MedTech startups or the equivalent country-specific post for your jurisdiction.

Common mistakes MedTech founders make with EU funding

Four patterns repeat across the MedTech founders we have watched misread the EU funding stack.

Treating the EU stack as one thing. Founders who say they are "applying for EU funding" without specifying which instrument have not yet done the orientation work. Each instrument is distinct, and an application written for the wrong one cannot be recovered by polish.

Copying the structure of a consortium proposal into a single-company application. Horizon Europe collaborative proposals and EIC Accelerator single-company proposals answer different questions for different readers. A proposal written in the voice of a consortium does not translate into a single-company application and vice versa.

Underestimating the preparation time. Serious EU applications take months of concentrated work, not weeks. Founders who start a few weeks before the cut-off lose the months of preparation the evaluators are looking for and rarely clear the early stages.

Ignoring the regulatory dimension. The MedTech-literate evaluators on EU panels read regulatory sections critically. An application that gestures vaguely at CE marking under MDR without naming the intended purpose, the risk class, the classification rule, the conformity assessment route, and the clinical evidence pathway signals that the team has not engaged with the regulatory reality yet. Every euro of EU funding still sits under the full obligations of Regulation (EU) 2017/745, Article 10.

The Subtract to Ship angle on EU funding

The Subtract to Ship framework applied to EU funding is not "apply to everything on the EU stack." It is "identify the one or two instruments that actually fit this project, cut the rest from the plan, and prepare the strong applications rather than the rushed ones."

The subtraction discipline here has two edges. On the opportunity side, it says that the EU instruments that actually match the project are worth the months of preparation, because the alternative. Giving up the same amount of equity for the same amount of capital. Is far more expensive on a multi-year horizon than founders feel in the moment. On the constraint side, it says that every EU instrument that does not fit the project should be struck from the plan early, before the time cost of a bad-fit application is paid. A founder who applies to one instrument seriously and does not apply to three others has more total funding optionality than a founder who applies to all four badly.

The test inside each application is the same test the framework applies everywhere: does this section, this claim, this figure trace to something the panel needs to know to evaluate the project against the criteria of this specific instrument? If yes, keep it. If no, cut it. The evaluators read faster than applicants believe, and the application that reads cleanly and wastes no space has a real advantage over the one that meanders.

Reality Check. Where do you stand?

  1. Can you name each of the major EU instruments in the stack and explain in one sentence what each one actually funds?
  2. Have you identified the one or two instruments that actually fit your project, and can you defend that choice against a skeptical reader?
  3. Is your project at a stage where the instruments you are targeting are realistically open to you, or are you applying too early or too late?
  4. Do you have months of preparation time available before the cut-offs you are targeting, or are you planning to rush a submission?
  5. Is your regulatory plan detailed enough to survive MedTech-literate review. Intended purpose, risk class, classification rule, conformity assessment route, clinical evidence pathway?
  6. Have you verified current programme terms directly at the Commission portals, or are you working from figures in blog posts and slide decks?
  7. If every EU application you are planning failed, would the work you did on them still be useful to the company, or is it time you would regret?

Frequently Asked Questions

What is EU funding for MedTech startups? EU funding for MedTech startups is the set of EU-level non-dilutive and equity-style instruments operated by the European Union and its agencies to support research, innovation, and commercialisation. The main visible pieces are Horizon Europe as the multi-year research and innovation framework, the EIC Accelerator as the single-company flagship, EIT Health as the health-focused innovation community under the European Institute of Innovation and Technology, and a wider edge of instruments like the Innovation Fund, Digital Europe, and EU4Health that occasionally reach MedTech projects.

What is the difference between Horizon Europe and the EIC Accelerator? Horizon Europe is the EU's multi-year framework programme for research and innovation and typically funds consortia of partners across member states working on shared research questions. The EIC Accelerator is a single-company instrument sitting inside the Horizon Europe framework that funds individual companies with a combination of grant and equity-style investment. A MedTech startup is most often a partner inside a Horizon Europe consortium and a lead applicant for the EIC Accelerator.

What does EIT Health do? EIT Health is the health-focused knowledge and innovation community under the European Institute of Innovation and Technology. It is a network of universities, research institutes, hospitals, and companies that collectively operate accelerator programmes, translation programmes, matching and deal-flow programmes, and training programmes across Europe. For a MedTech startup, it is best engaged with as an ongoing relationship rather than as a single application for one envelope of capital.

Is the Innovation Fund relevant for MedTech? The EU Innovation Fund's primary audience is not MedTech, but it has occasionally supported MedTech projects where the fit was right. For most MedTech founders, it is not where to start. It is worth scanning for projects that sit at the boundary of MedTech and another sector. Environmental health, dual-use technology, deep-tech crossover. Where the programme's targeted audience overlaps with the project's scope.

How long do EU funding applications take? Plan months for serious preparation and additional months for multi-stage evaluation. From the decision to apply to the first euro of drawdown, six to twelve months is a reasonable expectation for most substantive EU instruments, and the EIC Accelerator in particular runs on the longer end. EU funding is a strategic instrument, not a rescue for a cash crisis.

Does winning EU funding reduce the MDR work for my device? No. Every obligation under Regulation (EU) 2017/745, Article 10, continues to apply regardless of the funding source. The grant finances the regulatory work; it does not replace it. Treating EU funding as a substitute for doing the MDR work properly is one of the signals evaluators on MedTech panels catch quickly.

Sources

  1. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices. Article 10 (manufacturer obligations). Official Journal L 117, 5.5.2017.
  2. Horizon Europe. EU research and innovation framework programme. https://research-and-innovation.ec.europa.eu. Verify current calls, consortium rules, and funding envelopes directly with the Commission before relying on specific figures.
  3. European Innovation Council. EIC Accelerator programme information. https://eic.ec.europa.eu. Verify current programme terms, cut-off dates, eligibility thresholds, and evaluation criteria directly before relying on any figure.
  4. EIT Health. The health knowledge and innovation community under the European Institute of Innovation and Technology. https://eithealth.eu. Verify current accelerator, translation, and matching programmes directly with the administering hubs before relying on specific figures.
  5. EU Innovation Fund, Digital Europe, EU4Health, InvestEU, and European Investment Fund instruments. Verify current programme terms directly at the Commission's portals for each instrument before relying on specific figures.

Note on current-terms verification: Every instrument, programme, and figure referenced in this post is framed at general level and reflects the pattern of the EU stack as it has operated historically. Specific calls, budgets, cut-off dates, eligibility thresholds, and evaluation criteria are defined in current work programmes and change through the framework cycles. Before any specific figure or programme from this post enters a business plan, pitch deck, or board document, confirm the current terms directly at the Commission's portals for the relevant instrument. This is a working rule, not a disclaimer.

This post is part of the Funding, Business Models & Reimbursement series in the Subtract to Ship: MDR blog. Authored by Felix Lenhard and Tibor Zechmeister. The EU funding stack is wider than one post can cover in depth, and the sequencing decisions that matter most are made before the first application is drafted. When the specific shape of your device, your regulatory plan, and your commercial story exceeds what an overview post can address, a sparring partner who has walked founders through the stack from orientation to submission is the shortest path to an EU funding plan you can actually run.